HomeQuestion
What are your top takeaways in Head & Neck Cancers from ASCO 2024?
3 Answers
Mednet Member
Medical Oncology · University of Michigan Medical School
- The PATHWay study Abstract 6008: checkpoint inhibitor therapy has become instrumental in the treatment of recurrent and metastatic head and neck squamous cell carcinomas. However, we still do not have data to inform us whether treatment with such agents is beneficial in the adjuvant setting. In thi...
Mednet Member
Medical Oncology · OSUCCC – James
There were many interesting abstracts in the Head and Neck section presented at ASCO this year. In addition to the abstracts presented on EBV and HPV-mediated cancers, the following three abstracts stood out to me in terms of novelty, drug development, and high unmet need.
Mednet Member
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
I would like to highlight the DIPPER study: Adjuvant PD-1 blockade with Camrelizumab in high-risk locoregionally advanced NPC- A multicenter, open-label, phase 3, randomized controlled trial by Ma et al.:
Adjuvant PD-1 inhibition significantly improved PFS in patients with NPC who received inductio...